LABT — Lakewood-Amedex Biotherapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079272 ·
Last close
$0.71
Market Cap
$9.98M
52W High
$9.82
52W Low
$0.66
ADV30
4,280,124
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -712,060 | -744,918 | 481,598 | 236,400 | 2,446,135 |
| Sep 2025 | 0 | — | -1,880,317 | -1,907,159 | 985,118 | 658,410 | 2,251,434 |
| Dec 2024 | 0 | — | -862,176 | -854,539 | 1,070,581 | 681,098 | 660,970 |
| Sep 2024 | 0 | — | -912,913 | -1,936,135 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,160,221
Investing CF
$841,000
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.28
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-53,351,130
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-5,367,135
Pretax Income TTM
$-5,442,751
Interest Exp TTM
$75,616
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,772,370 | -3,847,637 | 481,598 | 2,446,135 | — | -1,944,698 |
| Dec 2024 | 0 | -4,026,820 | -4,855,405 | 1,070,581 | 660,970 | — | -5,723,322 |
| Dec 2023 | 0 | -8,636,719 | -8,281,960 | 6,893,904 | 2,335,577 | — | -6,816,114 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JUNS | JUPITER NEUROSCIENCES, INC. | $9.99M | $0.23 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $9.86M | $5.13 | — |
| BFRI | Biofrontera Inc. | $10.18M | $0.80 | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $9.72M | $4.84 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $10.30M | $4.49 | — |
News headlines (Yahoo Finance, 1h cache)
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
2026-05-18 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
2026-05-12 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
2026-04-28 11:33 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
2026-04-23 14:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.